Candid Therapeutics will go public through a reverse merger as it seeks to prove whether T cell engagers can shake up the treatment of autoimmune diseases. The San Diego and Shanghai biotech …
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
